Simil Gala, MD
Interventional Cardiology · Green Bay, WINPI 1073716445
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novartis at 46.6% of the total. That places this record below the midpoint for interventional cardiology clinicians in WI, where the typical reported total is $3,713.
Across 162 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Medtronic$458
- Edwards Lifesciences$332
- AstraZeneca$285
- Boehringer Ingelheim$277
- E.r. Squibb & Sons, L.L.C.$234
- plus $742 from 13 others
Across 15 payments — averaging $38,928 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$568K
- Medtronic$16K
What the payments were for
- Food & beverage$4,27098%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 80 | $2,027 |
| Medtronic(2 entities) | 18 | $458 |
| Edwards Lifesciences | 7 | $332 |
| AstraZeneca | 16 | $285 |
| Boehringer Ingelheim | 9 | $277 |
| E.r. Squibb & Sons, L.L.C. | 11 | $234 |
| Gilead | 1 | $125 |
| Johnson & Johnson | 4 | $99 |
| Biotronik Inc. | 2 | $93 |
| Pfizer | 1 | $93 |
| Shockwave Medical, Inc | 3 | $78 |
| Boston Scientific | 1 | $70 |
| Bridgebio Pharma, Inc. | 2 | $51 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Heartflow, Inc. | 1 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Abiomed | 1 | $15 |
| Silk Road Medical, Inc. | 1 | $13 |
| Cardiovascular Systems Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,354 in reported general payments places this provider in the 50th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,242 | $1,506,428 |
| XareltoRivaroxaban | 247 | $333,804 |
| Repatha SureclickEvolocumab | 358 | $281,550 |
| EntrestoSacubitril/Valsartan | 186 | $219,370 |
| BrilintaTicagrelor | 104 | $80,460 |
| Praluent PenAlirocumab | 88 | $69,345 |
| JardianceEmpagliflozin | 50 | $67,442 |
| FarxigaDapagliflozin Propanediol | 34 | $29,613 |
| Metoprolol Succinate | 1,669 | $23,957 |
| MultaqDronedarone Hcl | 20 | $23,529 |
| Ezetimibe | 886 | $22,106 |
| Atorvastatin Calcium | 1,847 | $21,976 |
| VascepaIcosapent Ethyl | 25 | $20,808 |
| ClopidogrelClopidogrel Bisulfate | 1,093 | $15,324 |
| Diltiazem 12hr ErDiltiazem Hcl | 33 | $11,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $93 | $1,506,4281,242 claims |
| Johnson & JohnsonXarelto | $99 | $333,804247 claims |
| NovartisEntresto | $2,027 | $219,370186 claims |
| AstraZenecaBrilinta, Farxiga | $285 | $110,073138 claims |
| Boehringer IngelheimJardiance | $277 | $67,44250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Green Bay
- Paul HudsonGreen Bay$24K
- Sampoornima SettyGreen Bay$16K
- Sumit RingwalaGreen Bay$8K
- Kristopher SelkeGreen Bay$4K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.